Skip to main content
. 2017 Feb 6;8(17):27772–27785. doi: 10.18632/oncotarget.15115

Figure 6. B392 sensitized sirolimus anticancer activity in sirolimus-resistant cell line.

Figure 6

(A) Acute myeloid leukemia cell lines (HL60, MV4-11, MOLM-13) and lymphoblastic cell lines (MOLT-4, CCRF-CEM) were treated with indicated concentration of sirolimus for 48, 72, 96 h. The cell viability was determined by MTT assay. The right table summarizes the IC50 of sirolimus at 72 h. IC50 values were calculated by sigmoidal dose-response equation and expressed as mean plus minus SD. (B) The cell viability of B392 combined with sirolimus at 72 h. (C) The expression of caspase 3, PARP, p-AKT, t-AKT, p-mTOR, t-mTOR, p-P70S6K, P70S6K, p-4EBP1, 4EBP, Mcl-1 and actin was determined after 0.03 μM B392 combination with 5 μM or 10 μM sirolimus for 72 h. S: sirolimus **P < 0.01, ***P < 0.001.